Study of Early Blood Cancers and Precursor Conditions to Understand Molecular Changes and Clinical Outcomes

What this Trial Is About

Researchers are investigating precursor hematological cancers, such as early myelodysplastic syndromes MDS, monoclonal gammopathy of undetermined significance MGUS, smoldering multiple myeloma, and other low-grade blood cancers. This study aims to understand the genetic and molecular changes that occur in these blood cancers and how they relate to disease progression and clinical outcomes. By analyzing these molecular alterations, scientists hope to improve prevention and treatment strategies for blood cancers. The study uses tissue samples already collected during participants clinical care, including blood, bone marrow, lymph nodes, urine, and other specimens. Additional samples may be collected for research purposes, such as a small blood sample or a gentle cheek swab to obtain normal cells for comparison. Researchers may create living cell lines from the tissue samples for future studies. Participant specimens and data may be stored securely and shared with research repositories to aid in further genetic research. Participants will not undergo extra clinical tests beyond their usual care but will be asked for permission to use their samples and clinical information. Follow-up visits will be conducted at regular intervals to monitor disease progression risk. The main outcome measured is identifying molecular changes in patients cells over a 10-year period. Throughout the study, privacy and confidentiality of participant information will be protected, and no additional risks beyond routine care are expected.

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome